Bay Area's Ultragenyx Swoops in With $138 Million Bid for Almost-Sold Dimension Therapeutics

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-stocks4.jpg" NAME"Bay Area's Ultragenyx Swoops in With $138 Million Bid for Almost-Sold Dimension Therapeutics" ALT"Bay Area's Ultragenyx Swoops in With $138 Million Bid for Almost-Sold Dimension Therapeutics"September 18, 2017By…

Continue ReadingBay Area's Ultragenyx Swoops in With $138 Million Bid for Almost-Sold Dimension Therapeutics

Nabriva's Stock Explodes as Pneumonia Drug Wows in Two Phase III Trials

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x430-stock-positive.jpg" NAME"Nabriva's Stock Explodes as Pneumonia Drug Wows in Two Phase III Trials" ALT"Nabriva's Stock Explodes as Pneumonia Drug Wows in Two Phase III Trials"September 18, 2017By Alex Keown,…

Continue ReadingNabriva's Stock Explodes as Pneumonia Drug Wows in Two Phase III Trials

Novartis AG Unloads Former New York Space for $18 Million, Resold for $30 Million

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x600-novartis.jpg" NAME"Novartis Unloads Former New York Space for $18 Million, Resold for $30 Million" ALT"Novartis Unloads Former New York Space for $18 Million, Resold for $30 Million"September 15, 2017By…

Continue ReadingNovartis AG Unloads Former New York Space for $18 Million, Resold for $30 Million

Bavarian Nordic Plummets 49% After Cancer Vaccine Flunks Late-Stage Test

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-stocks2.jpg" NAME"Bavarian Nordic Plummets 49% After Cancer Vaccine Flunks Late-Stage Test" ALT"Bavarian Nordic Plummets 49% After Cancer Vaccine Flunks Late-Stage Test"September 15, 2017By Alex Keown, BioSpace.com Breaking... Source: BioSpace

Continue ReadingBavarian Nordic Plummets 49% After Cancer Vaccine Flunks Late-Stage Test